Novo Nordisk Rises 2.8% as Split Analyst Views Set Up a November Reckoning
Published on 10/08/2026 at 04:41 | Editorial boerse-global.de
Shares of Novo Nordisk closed Wednesday's session at EUR 34.06, a gain of 2.8% on the day that lifted the stock's seven-day performance to a 2.2% advance. No company-specific catalyst was behind the move, leaving investors to focus on the Danish drugmaker's upcoming calendar and the trajectory of its core business.
Attention now converges on November 4, 2026, when Novo Nordisk will publish financial results for the first three quarters at 07:30 CET. The report is expected to shed light on demand for the company's flagship products and provide a financial snapshot of the group's progress through the year. Market participants, still digesting recent price swings, are looking for fresh fundamental signals from operations — particularly momentum in clinical development and management's assessment of the full-year outlook.
Deutsche Bank Cuts, J.P. Morgan Holds Firm
Analyst opinion heading into that print is sharply divided. Deutsche Bank Research lowered its price target to DKK 225 from DKK 245, according to media reports, while keeping a Sell rating on the stock. J.P. Morgan struck a more constructive tone on Monday, maintaining a Neutral rating with a DKK 275 target.
The split hinges on a single question: how much real demand exists for oral Wegovy. J.P. Morgan argued Monday that better-than-expected uptake of the tablet could meaningfully lift third-quarter results and hand the company valuable breathing room. Should that momentum fail to materialize, the high growth assumptions underpinning the stock would come under pressure. In the bullish scenario, an upside surprise on oral Wegovy could even prompt Novo Nordisk to raise its full-year guidance — a revision that would ease the recent downward pressure and potentially bring investors back quickly.
Deutsche Bank, by contrast, flagged the EASD conference results as a mildly negative factor and cited fresh real-world data on Wegovy and Ozempic presented roughly a week earlier, which failed to dispel its reservations.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Buybacks and Licensing Deals Underpin the Pipeline
Supporting the more optimistic case are Novo Nordisk's continuing repurchases. The company reported Monday that it bought back 1,225,000 B-shares for DKK 307.4 million between September 28 and October 2. The transactions form part of an DKK 11.2 billion program within a broader buyback of up to DKK 15 billion — a signal of management's confidence in its own earnings power. Longer-term pipeline backing also comes from agreements such as the licensing deal with Hengrui for HRS-1596, struck more than a month ago, though the stock has shed 27.9% since then.
FDA Extends Denecimig Review
Regulatory proceedings remain in the spotlight alongside the financial calendar. The US Food and Drug Administration has extended its review of the marketing application for Denecimig, a treatment for hemophilia A, because of ongoing remediation work at a manufacturing site. No new decision date has been set.
Crucially, the FDA did not identify any deficiencies in clinical efficacy or safety, according to Novo Nordisk. The company also stressed that the delay does not affect its financial outlook for 2026 and continues to target a US market launch in the first half of 2027, subject to regulatory approval.
Liver-Fat Data and CagriSema Results
The research pipeline delivered fresh scientific findings in parallel. On October 1, Novo Nordisk presented data at the EASD specialist conference on the use of Wegovy: after 72 weeks of treatment, 88.5% of participants with elevated liver fat saw their liver fat levels normalize.
The company also unveiled data at the conference for its drug candidate CagriSema. The studies showed positive effects on bone and organ health, along with a reduction in "food noise" — the persistent mental preoccupation with eating.
The 52-Week Low Is the Line in the Sand
Technically, the picture narrows to a single level. As long as support at the 52-week low of EUR 30.25 holds, the chance of stabilization remains intact. Should confidence in revenue momentum erode before the quarterly figures land, a fresh test of that floor becomes likely, leaving investors with little room to maneuver.
The November 4 report will ultimately determine whether J.P. Morgan's optimistic scenario or Deutsche Bank's cautious stance carries the day. Until those hard numbers arrive, the market's posture remains one of tactical caution.
Ad
Novo Nordisk Stock: New Analysis - 8 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
